Trimeris (TRMS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who started this subject	6/3/2004 7:54:14 PM
From: mopgcw	Read Replies (1) of 108

GS: Trimeris, Inc. EPS (FY Dec) 2004E ($1.07), 2005E $0.10 Outperform/Neutral (TRMS) $14.71 Trimeris announced after the close that Dr. M. Nixon Ellis, President, is leaving the company by mutual agreement. Trimeris has begun a search to replace Dr. Ellis with a candidate with significant commercial experience. We believe that this move is reflective of the company's emphasis on commercial development. We believe that Dr. Ellis' expertise was in clinical development and strategic planning, where he made significant contributions to the development and approval of HIV drug Fuzeon. We do not expect that the management change will impact Trimeris stock price. Based on our long-term conviction in Fuzeon and current valuation, we maintain an OutPerform rating on Trimeris and Neutral coverage view. However, we expect that it will continue to take time to build the market for Fuzeon. Several important initiatives have only recently been initiated and script trends continue to be gradual. The key risk for the stock is lack of sufficient pick up in Fuzeon sales.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next